title: Effect of telmisartan 80 mg once daily on 24-h blood pressure profile in patients with mild-to-moderate hypertension failing to respond to prior antihypertensive therapy.
abstract: Blood pressure is not adequately controlled in almost 50% of patients with hypertension who are in receipt of antihypertensive therapy. This multicentre, prospective, open-label trial was designed to determine whether or not once-daily telmisartan 80 mg reduced blood pressure during the last 6 h of the 24-h dosing interval in patients with mild-to-moderate hypertension who were unresponsive to previous antihypertensive therapy. The study comprised 100 patients (47 males, 53 females) who had failed to respond satisfactorily to prior treatment given for a minimum of 3 months. At screening, 24-h ambulatory blood pressure monitoring (ABPM) was conducted after the patient had been treated with the currently prescribed antihypertensive medication. Following 5 weeks of telmisartan 80 mg treatment, ABPM was repeated. Telmisartan significantly reduced mean systolic blood pressure, diastolic blood pressure (DBP) and pulse pressure compared with previous antihypertensive therapy over each time interval (24-h, morning, night-time and the last 6 h of the dosing interval [2.00 a.m.-8.00 a.m.]) analysed. In addition, more than 90% of patients responded successfully (clinic DBP <90 mmHg or a >10 mmHg reduction in clinic DBP) at the end of telmisartan treatment. In conclusion, telmisartan provides effective blood pressure control throughout the 24-h dosing interval in patients with mild-to-moderate hypertension who were unresponsive to previous antihypertensive medication.
authors.affiliation: Instituto de Investigación Cardiovascular, Universidad de Guadalajara, Hospital Civil Dr Juan I. Menchaca, Guadalajara, México. jzparra@mail.hcg.udg.mx
authors.forename: J Z
authors.initials: JZ
authors.lastname: Parra Carrillo
authors.forename: M
authors.initials: M
authors.lastname: Fernández
authors.forename: M
authors.initials: M
authors.lastname: Barrera
authors.forename: J
authors.initials: J
authors.lastname: Bahena
authors.forename: M
authors.initials: M
authors.lastname: Estrella
authors.forename: R
authors.initials: R
authors.lastname: Olivares Ruiz
authors.forename: L
authors.initials: L
authors.lastname: Lepe
authors.forename: R
authors.initials: R
authors.lastname: Arriaga
authors.forename: C
authors.initials: C
authors.lastname: Bonilla
authors.forename: S
authors.initials: S
authors.lastname: Fonseca
authors.forename: S
authors.initials: S
authors.lastname: Miranda
authors.forename: C
authors.initials: C
authors.lastname: Segovia
authors.forename: M D C
authors.initials: MD
authors.lastname: García Luna Viesca
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D047228:Angiotensin II Type 1 Receptor Blockers / Q000008:administration & dosage*; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000008:administration & dosage*; D000959:Antihypertensive Agents / Q000008:administration & dosage*; D001562:Benzimidazoles / Q000008:administration & dosage*; D001565:Benzoates / Q000008:administration & dosage*; D001794:Blood Pressure / Q000502:physiology*; D005260:Female; D006801:Humans; D006973:Hypertension / Q000188:drug therapy* / Q000503:physiopathology; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D000077333:Telmisartan; D016896:Treatment Outcome
chemical_list: D047228:Angiotensin II Type 1 Receptor Blockers; D000806:Angiotensin-Converting Enzyme Inhibitors; D000959:Antihypertensive Agents; D001562:Benzimidazoles; D001565:Benzoates; D000077333:Telmisartan